Merrimack Pharmaceuticals and sanofi-aventis announced that the first patient has received an initial dose in a Phase 2 study combining MM-121 with Aromasin (exemestane) for the treatment of breast cancer.

Onyx Pharmaceuticals announced that it has begun enrollment in a Phase 3 trial evaluating carfilzomib in combination with Revlimid (lenalidomide) and low dose dexamethasone in patients with relapsed multiple myeloma.

Arcion Therapeutics announced positive results from a Phase 2b, double-blind, randomized, placebo-controlled clinical trial of ARC-4558 (clonidine HCl 0.1% topical gel) in patients with painful diabetic neuropathy (PDN).

Bristol-Myers Squibb and Otsuka announced that the supplemental New Drug Application (sNDA) for Sprycel (dasatinib) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase has been accepted for filing and granted priority review by the FDA.

Sangart, Inc. announced that enrollment was completed in a Phase 2a study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis.

InteKrin Therapeutics announced results from its Phase 2b study of INT131 for the treatment of type 2 diabetes.

Isis Pharmaceuticals announced the presentation of data from its clinical trials of ISIS 113715 and ISIS-GCGRRx for the treatment of diabetes.

Sangamo BioSciences announced positive Phase 2 data from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy (DN).

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

Orexigen announced data from its COR-Diabetes trial for Contrave (naltrexone sustained release (SR)/bupropion SR) for weight lowering and improved glycemic control in obese patients with type 2 diabetes.